🇺🇸 FDA
Pipeline program

AMG386 plus PLD

20060517

Phase 3 small_molecule terminated

Quick answer

AMG386 plus PLD for Fallopian Tube Cancer is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen
Indication
Fallopian Tube Cancer
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials